OncoMatch/Clinical Trials/NCT07221058
Adaptive Radiation Boost for Rectal Cancer
Is NCT07221058 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies non-drug interventions for rectum cancer, adenocarcinoma.
The goal of this clinical trial is to find out if giving extra adaptive radiation therapy after standard chemoradiation treatment is safe and helpful for people with rectal cancer. The main questions the study aims to answer are: * Can this approach help target the most aggressive cancer cells more accurately, while protecting nearby healthy tissue? * Can it reduce the side effects that people may experience during treatment? Participants will: * First receive standard treatment: radiation (45 Gy in 25 sessions) along with a chemotherapy pill called capecitabine. * Then get extra radiation using MRI scans every two weeks to adjust the treatment based on how the tumor responds. * Use a small balloon during treatment to help aim the radiation and protect healthy areas. * Finally, receive additional chemotherapy (such as FOLFOX) for four months.
Check if I qualifyExtracted eligibility criteria
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: any therapy for rectal cancer
Subjects who have been previously treated for rectal cancer are excluded.
Cannot have received: pelvic radiation
Subjects may not have had prior pelvic radiation.
Lab requirements
Blood counts
absolute neutrophil count >=1,000/mcl; platelets >= 75,000/mcl
Liver function
total bilirubin < 3 mg/dl
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Fox Chase Cancer Center · Philadelphia, Pennsylvania
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify